RHÖN-KLINIKUM Aktiengesellschaft AI Price Prediction

With EPS at €0.60 and a PE ratio of 22.56, RHÖN-KLINIKUM is priced at a moderate earnings multiple that suggests neither deep value nor clear overvaluation based solely on earnings. The profitability implied by the EPS is positive but not exceptionally strong relative to the valuation, pointing to a fairly balanced risk‑reward profile. Absent detailed revenue and margin trends, the current data point to a steady but not strongly accelerating earnings story.

• EPS of €0.60 indicates the company is profitable, but without high growth signals from the limited data provided.
• A PE ratio of 22.56 is in a mid‑range that suggests the market is pricing in stable to modest growth rather than deep distress or exuberant optimism.
• The combination of moderate earnings and valuation implies a fairly valued stock on fundamentals, pending more detailed information on revenue growth and margin trends.

The stock at €13.50 is trading above its 200‑day moving average of €12.58 and has gained 7.1% over the last month, indicating a short‑term positive trend. An RSI of 57.01 is comfortably in neutral territory, suggesting the stock is neither overbought nor oversold. Overall, technicals lean mildly positive but do not yet signal a strong momentum breakout.

• Current price of €13.50 is about 7.3% above the 200‑day moving average (€12.58), indicating a modest upward trend and improving medium‑term sentiment.
• A 7.1% gain over the last month shows recent buying interest but not extreme momentum.
• RSI at 57.01 sits in a neutral zone (30–70), implying balanced buying and selling pressure without clear overbought/oversold conditions.

Overall sentiment on RHÖN-KLINIKUM Aktiengesellschaft appears neutral. Fundamentals and valuation look balanced, technicals show a mild upward bias without overextension, and alternative data are weighed down by a steep decline in job postings despite small positive signals in social engagement. The stock does not currently present a strongly bullish or bearish setup based on the available information.

• Earnings and valuation (EPS €0.60, PE 22.56) suggest a reasonably priced, profitable company without clear evidence of strong acceleration or deterioration.
• Price trading above the 200‑day moving average with a neutral RSI points to a modestly positive trend but not a strong momentum story.
• A sharp drop in job openings and only modest alternative‑data strength temper the outlook, resulting in an overall neutral stance.